Healthcare Industry News: TLIF
News Release - August 15, 2007
Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
RESEARCH TRIANGLE PARK, N.C., Aug. 15 (HSMN NewsFeed) -- Quintiles Transnational Corp. today announced the appointment of Michael Troullis as its Chief Financial Officer, effective immediately. Troullis had been acting CFO since former CFO John RaTLIFf was appointed Quintiles' Chief Operating Officer last year.Troullis joined Quintiles in 1992 as Director of Finance, Europe. Prior to his appointment as acting CFO, Troullis was Senior Vice President and Worldwide Controller.
"Mike's financial expertise and deep knowledge of Quintiles and our markets make him the best person to be the fourth CFO in Quintiles' 25-year history," said Dennis Gillings, CBE, Chairman and Chief Executive Officer of Quintiles Transnational. "He has helped put in place the financial systems and controls needed to support Quintiles' growth from a small CRO to being the global leader in helping companies bring medicines to market faster and more efficiently."
Troullis, who will report to Gillings, has a bachelor's degree in Economics from the University of Exeter (England) and is qualified as a United Kingdom Chartered Accountant.
Prior to joining Quintiles, Troullis had a 10-year career with CooperVision, where he held several positions of increasing responsibility, finally as European Finance Director; and six years with KPMG in the United Kingdom.
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With about 19,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at www.qtrn.com
Source: Quintiles Transnational
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
